CoChat
Sign Up
Cited by 253Hormonal and reproductive studiesPharmaceutical industry and healthcareAdrenal Hormones and Disorders

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Global trends in testosterone prescribing, 2000–2011: expanding the spectrum of prescription drug misuse

Handelsman, David J·2013·Medical Journal of Australia
DOI 10.5694/mja13.10111
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To provide the first multinational survey of temporal trends in testosterone prescribing, given that anecdotal evidence indicates that it is increasing in some countries, including Australia. DESIGN: Sales data for all testosterone products were obtained for 41 countries for each year from 2000 to 2011. For each testosterone product type (injectable, implantable, oral, transdermal), units sold were converted into defined monthly doses per year, reflecting total testosterone prescribing per product. MAIN OUTCOME MEASURES: National testosterone prescribing rate overall and per product type on a per capita basis. RESULTS: For every region and 37 of 41 countries, there was a major and progressive increase in defined monthly doses per year per capita over the 11 years surveyed. In most countries, the increases were steeper for the last half of the survey period. The proportion of testosterone prescribing represented by transdermal testosterone products, a surrogate measure of prescribing for older men, increased even more than did the total usage of testosterone products. CONCLUSIONS: In the absence of any new indications, off-label testosterone prescribing has increased in most countries in 2000-2011, especially over the last half of the period. The increased testosterone prescribing appears to be primarily for older men and driven by clinical guidelines that endorse testosterone prescribing for age-related functional androgen deficiency (andropause). By eliminating the fundamental distinction between pathological and functional androgen deficiency, these guidelines tacitly promote increased testosterone prescribing, bypassing the requirement for high-quality clinical evidence of safety and efficacy and creating dramatic increases in prescription of testosterone products.

Overview

Integrity signals

Registry

Crossref · 10.5694/mja13.10111

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Research works printed but not linked: 1

  1. Braun SR, 2013, Promoting “low T”: a medical writer's perspective, JAMA Intern Med

Cited by

Sorted by citations

See all 253

Related

Metadata

Authors
Handelsman, D. J.
Affiliations
The University of Sydney (AU)
Corresponding author
Handelsman, David J
ORCID
Handelsman, David J
Venue
Medical Journal of Australia
Publisher
AMPCo
Published
2013-10
Volume
199
Issue
8
Pages
548-551
ISSN
  • 0025-729X (ISSN-L)
  • 1326-5377
DOI
10.5694/mja13.10111
OpenAlex
W2068541344
Cited by
253
References
34
Citations by year
2026: 12 · 2025: 18 · 2024: 15 · 2023: 14 · 2022: 19 · 2021: 14 · 2020: 18 · 2019: 12 · 2018: 26 · 2017: 32 · 2016: 21 · 2015: 30 · 2014: 22
FWCI
19.14
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • The Medical Journal of Australia (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
prescription drug misuse, off-label drug use, andropause, transdermal testosterone, testosterone implants, clinical guidelines, older men
MeSH terms
Australia, Cross-Cultural Comparison, Forecasting, Health Surveys, Humans, Male, Practice Patterns, Physicians', Testosterone, Health Care Costs, Evidence-Based Medicine, Hormone Replacement Therapy, Andropause, Off-Label Use, Prescription Drug Misuse

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review